Effect of cisapride on esophageal pH monitoring in children with reflux-associated bronchopulmonary disease

J Pediatr Gastroenterol Nutr. 1989 Apr;8(3):327-32. doi: 10.1097/00005176-198904000-00011.

Abstract

Clinical evaluation and prolonged esophageal pH monitoring were performed before and during treatment with cisapride (0.3 mg/kg t.i.d.) for 1 month in 19 children with reflux-associated bronchopulmonary disease. Results (mean +/- SEM) show that cisapride significantly decreases the frequency of long duration (greater than 5 min) reflux episodes (from 9.7 +/- 0.7 to 5.7 +/- 1.2), the percentage of total time pH was less than 4 (from 15.9 +/- 2.5 to 7.7 +/- 1.1%), the percentage of time pH was less than 4 at night (from 18.0 +/- 3.9 to 4.9 +/- 1.5%), the duration of the longest reflux episodes (from 44.5 +/- 6.4 to 19.7 +/- 2.7 min), as well as the duration of reflux at night (from 100.1 +/- 28.0 to 28.2 +/- 10.1 min). The frequency of reflux episodes, however, remains unaffected by cisapride. Cough fits at night disappeared completely in 12 out of 13 children. We conclude that cisapride given for 1 month significantly decreased gastroesophageal reflux as well as cough episodes at night.

MeSH terms

  • Bronchial Diseases / complications
  • Child
  • Child, Preschool
  • Cisapride
  • Female
  • Gastroesophageal Reflux / complications
  • Gastroesophageal Reflux / drug therapy*
  • Humans
  • Hydrogen-Ion Concentration
  • Infant
  • Lung Diseases / complications*
  • Male
  • Monitoring, Physiologic
  • Piperidines / therapeutic use*
  • Serotonin Antagonists / therapeutic use*

Substances

  • Piperidines
  • Serotonin Antagonists
  • Cisapride